2型糖尿病患者的餐后血脂与动脉粥样硬化的研究进展

doi:10.3969/j.issn.1673-8640.2024.08.017

摘要/Abstract

摘要：

2型糖尿病（T2DM）患者血管病变的病理生理学机制复杂，易出现动脉粥样硬化，导致血管腔狭窄，最终引发冠状动脉粥样硬化性心脏病、缺血性卒中等严重心脑血管疾病和糖尿病足、截肢等严重并发症。血脂异常是动脉粥样硬化的高危因素，过去多以空腹血脂来代表个体的血脂状态。然而，餐后血脂才是1 d内占主导地位的脂类状态，是全天最真实的状态。餐后高脂血症是糖尿病脂代谢异常的重要特征，并可能促进动脉粥样硬化。文章对T2DM患者血脂的变化特点、餐后血脂与动脉粥样硬化的关系等方面的研究进展进行综述。

关键词: 餐后血脂, 2型糖尿病, 动脉粥样硬化

Abstract:

The pathophysiological mechanism of vascular disease in type 2 diabetes mellitus（T2DM） is complex，and atherosclerosis is prone to occur，leading to vascular stenosis，and eventually leading to coronary atherosclerotic heart disease，ischemic stroke and other serious cardiovascular and cerebrovascular diseases，as well as diabetic foot，amputations and other serious complications. Dyslipidemia is a high risk factor for atherosclerosis. In the past，fasting lipids were used to represent the status of individual lipids. However，postprandial lipids are the dominant lipid state within 1 d and are the most true state throughout the day. Postprandial hyperlipemia is an important characteristic of abnormal lipid metabolism in diabetes mellitus and may promote atherosclerosis. This review focuses on the changes of blood lipids in T2DM patients and the relationship between postprandial blood lipids and atherosclerosis.

Key words: Postprandial lipids, Type 2 diabetes mellitus, Atherosclerosis

中图分类号:

R446.1

钟玉华, 林铭旭, 师柔, 蒿自睿, 李桂平. 2型糖尿病患者的餐后血脂与动脉粥样硬化的研究进展[J]. 检验医学, 2024, 39(8): 815-819.

ZHONG Yuhua, LIN Mingxu, SHI Rou, HAO Zirui, LI Guiping. Research progress of postprandial lipids and atherosclerosis in patients with type 2 diabetes mellitus[J]. Laboratory Medicine, 2024, 39(8): 815-819.

参考文献 43

[1]	LUO J Q, SHU Y, ZHANG W. Editorial:pharmacogenomics and pharmacomicrobiomics in type 2 diabetes mellitus(T2DM)[J]. Front Endocrinol(Lausanne), 2023, 14:1287807.
[2]	LIU L, ZHANG J, CHENG Y, et al. Gut microbiota:a new target for T2DM prevention and treatment[J]. Front Endocrinol(Lausanne), 2022, 13:958218.
[3]	SUN H, SAEEDI P, KARURANGA S, et al. IDF Diabetes Atlas:global,regional and country-level diabetes prevalence estimates for 2021 and projections for 2045[J]. Diabetes Res Clin Pract, 2022, 183:109119.
[4]	中华医学会糖尿病学分会. 中国2型糖尿病防治指南(2020年版)[J]. 中华糖尿病杂志, 2021, 13(4):315-409.
[5]	JELLINGER P S, HANDELSMAN Y, ROSENBLIT P D, et al. American Association of Clinical Endocrinologists and American College of Endocrinology guidelines for management of dyslipdemia and prevention of cardiovascular disease[J]. Endocr Pract, 2017, 23(Suppl 2):1-87.
[6]	LIM S, KIM Y J, KHANG A R, et al. Postprandial dyslipidemia after a standardized high-fat meal in BMI-matched healthy individuals,and in subjects with prediabetes or type 2 diabetes[J]. Clin Nutr, 2021, 40(11):5538-5546.
[7]	KATSI V, PAPAKONSTANTINOU I, TSIOUFIS K. Atherosclerosis,diabetes mellitus,and cancer:common epidemiology,shared mechanisms,and future management[J]. Int J Mol Sci, 2023, 24(14):11786.
[8]	MOHSENI-MOGHADDAM P, GHOBADIAN R, KHALEGHZADEH-AHANGAR H. Dementia in diabetes mellitus and atherosclerosis:two interrelated systemic diseases[J]. Brain Res Bull, 2022, 181:87-96.
[9]	POZNYAK A, GRECHKO A V, POGGIO P, et al. The diabetes mellitus-atherosclerosis connection:the role of lipid and glucose metabolism and chronic inflammation[J]. Int J Mol Sci, 2020, 21(5):1835.
[10]	LI J, DONG Z, WU H, et al. The triglyceride-glucose index is associated with atherosclerosis in patients with symptomatic coronary artery disease,regardless of diabetes mellitus and hyperlipidaemia[J]. Cardiovasc Diabetol, 2023, 22(1):224.
[11]	CHAHAL J, GUPTA S, CHAWLA S, et al. Comparative study on fasting and postprandial lipid profile in type 2 diabetes mellitus[J]. J Family Med Prim Care, 2021, 10(3):1288-1293. DOI PMID
[12]	SHOJAEE-MORADIE F, MA Y, LOU S, et al. Prandial hypertriglyceridemia in metabolic syndrome is due to an overproduction of both chylomicron and VLDL triacylglycerol[J]. Diabetes, 2013, 62(12):4063-4069.
[13]	XIE W, BIAN W, SONG Z, et al. Association between triglyceride-glucose index and carotid atherosclerosis in patients with psoriatic arthritis[J]. Rheumatology(Oxford), 2023, 62(11):3584-3591.
[14]	YU H, TAO L, LI Y G, et al. Association between triglyceride-glucose index trajectories and carotid atherosclerosis progression[J]. Cardiovasc Diabetol, 2023, 22(1):130. DOI PMID
[15]	DUEZ H, LAMARCHE B, UFFELMAN K D, et al. Hyperinsulinemia is associated with increased production rate of intestinal apolipoprotein B-48-containing lipoproteins in humans[J]. Arterioscler Thromb Vasc Biol, 2006, 26(6):1357-1363. PMID
[16]	FEDERICO L M, NAPLES M, TAYLOR D, et al. Intestinal insulin resistance and aberrant production of apolipoprotein B48 lipoproteins in an animal model of insulin resistance and metabolic dyslipidemia:evidence for activation of protein tyrosine phosphatase-1B,extracellular signal-related kinase,and sterol regulatory element-binding protein-1c in the fructose-fed hamster intestine[J]. Diabetes, 2006, 55(5):1316-1326.
[17]	NOGUEIRA J P, MARANINCHI M, BELIARD S, et al. Absence of acute inhibitory effect of insulin on chylomicron production in type 2 diabetes[J]. Arterioscler Thromb Vasc Biol, 2012, 32(4):1039-1044.
[18]	HOGUE J C, LAMARCHE B, TREMBLAY A J, et al. Evidence of increased secretion of apolipoprotein B-48-containing lipoproteins in subjects with type 2 diabetes[J]. J Lipid Res, 2007, 48(6):1336-1342.
[19]	CHAN D C, WATTS G F, BARRETT P H, et al. Markers of triglyceride-rich lipoprotein remnant metabolism in visceral obesity[J]. Clin Chem, 2002, 48(2):278-283. PMID
[20]	WONG A T, CHAN D C, PANG J, et al. Plasma apolipoprotein B-48 transport in obese men:a new tracer kinetic study in the postprandial state[J]. J Clin Endocrinol Metab, 2014, 99(1):E122-E126.
[21]	TANG T, CHEN L. Correlation between serum ApoC Ⅲ and galectin-3 levels and maternal and neonatal adverse outcomes in gestational diabetes mellitus patients[J]. Emerg Med Int, 2022, 2022:5089529.
[22]	GIAMMANCO A, SPINA R, CEFALÙA B, et al. APOC-Ⅲ:a gatekeeper in controlling triglyceride metabolism[J]. Curr Atheroscler Rep, 2023, 25(3):67-76.
[23]	LAROUCHE M, KHOURY E, BRISSON D, et al. Inhibition of angiopoietin-like protein 3 or 3/8 complex and ApoC-Ⅲ in severe hypertriglyceridemia[J]. Curr Atheroscler Rep, 2023, 25(12):1101-1111.
[24]	BORÉN J, PACKARD C J, TASKINEN M R. The roles of ApoC-Ⅲ on the metabolism of triglyceride-rich lipoproteins inhumans[J]. Front Endocrinol(Lausanne), 2020, 11:474.
[25]	MALHOTRA P, BODDY C S, SONI V, et al. D-glucose modulates intestinal niemann-pick C1-like 1(NPC1L1)gene expression via transcriptional regulation[J]. Am J Physiol Gastrointest Liver Physiol, 2013, 304(2):G203-G210.
[26]	LALLY S, TAN C Y, OWENS D, et al. Messenger RNA levels of genes involved in dysregulation of postprandial lipoproteins in type 2 diabetes:the role of Niemann-Pick C1-like 1,ATP-binding cassette,transporters G5 and G8,and of microsomal triglyceride transferprotein[J]. Diabetologia, 2006, 49(5):1008-1016.
[27]	SIMONEN P P, GYLLING H K, MIETTINEN T A. Diabetes contributes to cholesterol metabolism regardless of obesity[J]. Diabetes Care, 2002, 25(9):1511-1515. DOI PMID
[28]	BRIAND F, THIÉBLEMONT Q, MUZOTTE E, et al. High-fat and fructose intake induces insulin resistance,dyslipidemia,and liver steatosis and alters in vivo macrophage-to-feces reverse cholesterol transport in hamsters[J]. J Nutr, 2012, 142(4):704-709.
[29]	HIYOSHI T, FUJIWARA M, YAO Z. Postprandial hyperglycemia and postprandial hypertriglyceridemia in type 2 diabetes[J]. J Biomed Res, 2017, 33(1):1-16.
[30]	TOMLINSON B, CHAN P, LAM C W K. Postprandial hyperlipidemia as a risk factor in patients with type 2 diabetes[J]. Expert Rev Endocrinol Metab, 2020, 15(3):147-157. DOI PMID
[31]	DING X, ZHOU H, YUE Q, et al. Association of trajectories of non-high-density lipoprotein cholesterol concentration with risk of cardiovascular disease:the Kailuan Study[J]. BMJ Open, 2023, 13(4):e69807.
[32]	DUNCAN M S, VASAN R S, XANTHAKIS V. Trajectories of blood lipid concentrations over the adult life course and risk of cardiovascular disease and all-cause mortality:observations from the framingham study over 35 years[J]. J Am Heart Assoc, 2019, 8(11):e11433.
[33]	KATSIKI N, TENTOLOURIS N, MIKHAILIDIS D P. Dyslipidaemia in type 2 diabetes mellitus:bad for the heart[J]. Curr Opin Cardiol, 2017, 32(4):422-429.
[34]	IDEI M, HIRAYAMA S, MIYAKE N, et al. Mean postprandial triglyceride concentration is an independent risk factor for carotid atherosclerosis in patients with type 2 diabetes[J]. Clin Chim Acta, 2014, 430:134-139. DOI PMID
[35]	ELSAYED N A, ALEPPO G, ARODA V R, et al. 10. Cardiovascular disease and risk management:standards of care indiabetes-2023[J]. Diabetes Care, 2023, 46(Suppl 1):S158-S190.
[36]	COSENTINO F, GRANT P J, ABOYANS V, et al. 2019 ESC guidelines on diabetes,pre-diabetes,and cardiovascular diseases developed in collaboration with the EASD[J]. Eur Heart J, 2020, 41(2):255-323.
[37]	JOSEPH J J, DEEDWANIA P, ACHARYA T, et al. Comprehensive management of cardiovascular risk factors for adults with type 2 diabetes:ascientific statement from the American Heart Association[J]. Circulation, 2022, 145(9):e722-e759.
[38]	KHAN S U, TALLURI S, RIAZ H, et al. A Bayesian network meta-analysis of PCSK9 inhibitors,statins and ezetimibe with or without statins for cardiovascular outcomes[J]. Eur J Prev Cardiol, 2018, 25(8):844-853.
[39]	KOSKINAS K C, SIONTIS G C M, PICCOLO R, et al. Effect of statins and non-statin LDL-lowering medications on cardiovascular outcomes in secondary prevention:a meta-analysis of randomized trials[J]. Eur Heart J, 2018, 39(14):1172-1180.
[40]	ZHU L, HAYEN A, BELL K J L. Legacy effect of fibrate add-on therapy in diabetic patients with dyslipidemia:a secondary analysis of the ACCORDION study[J]. Cardiovasc Diabetol, 2020, 19(1):28.
[41]	HU Y, HU F B, MANSON J E. Marine omega-3 supplementation and cardiovascular disease:an updated meta-analysis of 13 randomized controlled trials involving 127 477 participants[J]. J Am Heart Assoc, 2019, 8(19):e13543.
[42]	HUANG L, ZHANG F, XU P, et al. Effect of omega-3 polyunsaturated fatty acids on cardiovascular outcomes in patients with diabetes:a meta-analysis of randomized controlled trials[J]. Adv Nutr, 2023, 14(4):629-636.
[43]	CAMACHO-MUÑOZ D, KIEZEL-TSUGUNOVA M, KISS O, et al. Omega-3 carboxylic acids and fenofibrate differentially alter plasma lipid mediators in patients with non alcoholic fatty liver disease[J]. FASEB J, 2021, 35(11):e21976.